Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Melanoma, Neoplasms, Neoplasms, Unknown Primary, Penile Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Vulvar Neoplasms, Breast Neoplasms, Male

NCT01339663 2014-04-21

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Phase 1 Completed

12 enrolled

Dermatologic

Melanoma

NCT00445783 2013-08-12

Study of Families With Melanoma

Unknown

3,700 enrolled

Dermatologic

Melanoma

NCT00897481 2013-08-12

Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy

Unknown

1,000 enrolled

Dermatologic

Melanoma

NCT00438984 2012-03-16

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma

Phase 1 Completed

11 enrolled

Dermatologic

Melanoma

NCT00430053 2012-03-15

Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma

Completed

100 enrolled

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00602199 2011-05-16

ABT-510 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

42 enrolled

Dermatologic

Melanoma

NCT00667901 2009-12-11

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Phase 1 Terminated

15 enrolled

Dermatologic

Melanoma

Clinical Trials

Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma

Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690

Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

FDG-PET in Advanced Melanoma

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Study of Families With Melanoma

Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma

Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma

ABT-510 in Treating Patients With Metastatic Melanoma

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery